Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma

PURPOSE: Vismodegib is approved for the treatment of locally advanced basal cell carcinoma (laBCC), but some cases demonstrate intrinsic resistance (IR) to the drug. We sought to assess the frequency of IR to vismodegib in laBCC and its underlying genomic mechanisms. EXPERIMENTAL DESIGN: Response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yurchenko, Andrey A., Pop, Oltin T., Ighilahriz, Meriem, Padioleau, Ismael, Rajabi, Fatemeh, Sharpe, Hayley J., Poulalhon, Nicolas, Dreno, Brigitte, Khammari, Amir, Delord, Marc, Alberti, Antonio, Soufir, Nadem, Battistella, Maxime, Mourah, Samia, Bouquet, Fanny, Savina, Ariel, Besse, Andrej, Mendez-Lopez, Max, Grange, Florent, Monestier, Sandrine, Mortier, Laurent, Meyer, Nicolas, Dutriaux, Caroline, Robert, Caroline, Saiag, Philippe, Herms, Florian, Lambert, Jerome, de Sauvage, Frederic J., Dumaz, Nicolas, Flatz, Lukas, Basset-Seguin, Nicole, Nikolaev, Sergey I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365352/
https://www.ncbi.nlm.nih.gov/pubmed/35078858
http://dx.doi.org/10.1158/1078-0432.CCR-21-3764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365352/
https://www.ncbi.nlm.nih.gov/pubmed/35078858
http://dx.doi.org/10.1158/1078-0432.CCR-21-3764

Ejemplares similares